Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Medical Device

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System

Fineline Cube Dec 23, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO

Fineline Cube Dec 22, 2024

On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...

Company Drug

YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial

Fineline Cube Dec 21, 2024

Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...

Company Deals

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation

Fineline Cube Dec 21, 2024

Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful...

Company Deals

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing

Fineline Cube Dec 20, 2024

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...

Company Medical Device

Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use

Fineline Cube Dec 20, 2024

US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Fineline Cube Dec 20, 2024

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...

Company Drug

Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease

Fineline Cube Dec 20, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...

Company Deals

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments

Fineline Cube Dec 20, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...

Company Drug

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China

Fineline Cube Dec 20, 2024

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...

Company Deals

WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio

Fineline Cube Dec 20, 2024

China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...

Company Deals

MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil

Fineline Cube Dec 20, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...

Company Deals

Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB

Fineline Cube Dec 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...

Company Deals

BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal

Fineline Cube Dec 20, 2024

Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...

Company Deals

Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform

Fineline Cube Dec 20, 2024

China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...

Company Digital

Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights

Fineline Cube Dec 20, 2024

Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...

Company Deals

HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies

Fineline Cube Dec 20, 2024

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has...

Company Drug

Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Dec 20, 2024

China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...

Company Drug

Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment

Fineline Cube Dec 20, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with...

Company Deals

HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases

Fineline Cube Dec 20, 2024

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...

Posts pagination

1 … 264 265 266 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.